Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a lebanese population: Frequency distribution and association with morbid diseases

Nathalie Khoueiry Zgheib, Zahi Mitri, Eddy Geryess, Pakiza Noutsi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The drug-metabolizing enzyme CYP2E1 is of great interest in environmental medicine because of its involvement in the bioactivation of multiple procarcinogens. Aim: This study is aimed at determining the frequency of genetic polymorphisms of the three restriction fragment length polymorphisms: PstI and RsaI (CYP2E1*5B) and DraI (CYP2E1*6) in 216 cancer-free Lebanese individuals, as well as assessing potential association with morbid diseases in this specific population. Results: The frequency of C-T allele of CYP2E*5B was 0.7% and that of A CYP2E1*6 was 6.3%. All those who carried the CYP2E1*5B allele also carried the CYP2E1*6 allele. There was a significant decrease in coronary artery disease incidence in patients carrying a CYP2E1*6 genetic polymorphism (39.7% of the noncarriers vs. 13.6% of the carriers had coronary artery disease; p=0.019); similar results were found with the haplotype analysis (p=0.03) but not with CYP2E1*5B alone. Conclusion: This is the first study on the genetic polymorphism of CYP2E1 in a Lebanese population. These data will be useful for future assessment of the role of CYP2E1 polymorphisms in the cancer population in Lebanon. It is recommended that careful population selection be performed in designing case-control studies that evaluate the association between CYP2E1 and cancer incidence. The most important factors to be controlled for are sex, body mass index, environmental exposure, lifestyle habits, and possibly, history of coronary artery disease.

Original languageEnglish (US)
Pages (from-to)393-397
Number of pages5
JournalGenetic Testing and Molecular Biomarkers
Volume14
Issue number3
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Cytochromes
Demography
Coronary Artery Disease
Alleles
Population
Environmental Medicine
Lebanon
Neoplasms
Incidence
Environmental Exposure
Restriction Fragment Length Polymorphisms
Haplotypes
Habits
Case-Control Studies
Life Style
Body Mass Index

ASJC Scopus subject areas

  • Genetics(clinical)
  • Medicine(all)

Cite this

Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a lebanese population : Frequency distribution and association with morbid diseases. / Zgheib, Nathalie Khoueiry; Mitri, Zahi; Geryess, Eddy; Noutsi, Pakiza.

In: Genetic Testing and Molecular Biomarkers, Vol. 14, No. 3, 01.06.2010, p. 393-397.

Research output: Contribution to journalArticle

@article{6bb85472641a45efa6db93abddd1fb28,
title = "Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a lebanese population: Frequency distribution and association with morbid diseases",
abstract = "Background: The drug-metabolizing enzyme CYP2E1 is of great interest in environmental medicine because of its involvement in the bioactivation of multiple procarcinogens. Aim: This study is aimed at determining the frequency of genetic polymorphisms of the three restriction fragment length polymorphisms: PstI and RsaI (CYP2E1*5B) and DraI (CYP2E1*6) in 216 cancer-free Lebanese individuals, as well as assessing potential association with morbid diseases in this specific population. Results: The frequency of C-T allele of CYP2E*5B was 0.7{\%} and that of A CYP2E1*6 was 6.3{\%}. All those who carried the CYP2E1*5B allele also carried the CYP2E1*6 allele. There was a significant decrease in coronary artery disease incidence in patients carrying a CYP2E1*6 genetic polymorphism (39.7{\%} of the noncarriers vs. 13.6{\%} of the carriers had coronary artery disease; p=0.019); similar results were found with the haplotype analysis (p=0.03) but not with CYP2E1*5B alone. Conclusion: This is the first study on the genetic polymorphism of CYP2E1 in a Lebanese population. These data will be useful for future assessment of the role of CYP2E1 polymorphisms in the cancer population in Lebanon. It is recommended that careful population selection be performed in designing case-control studies that evaluate the association between CYP2E1 and cancer incidence. The most important factors to be controlled for are sex, body mass index, environmental exposure, lifestyle habits, and possibly, history of coronary artery disease.",
author = "Zgheib, {Nathalie Khoueiry} and Zahi Mitri and Eddy Geryess and Pakiza Noutsi",
year = "2010",
month = "6",
day = "1",
doi = "10.1089/gtmb.2009.0193",
language = "English (US)",
volume = "14",
pages = "393--397",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a lebanese population

T2 - Frequency distribution and association with morbid diseases

AU - Zgheib, Nathalie Khoueiry

AU - Mitri, Zahi

AU - Geryess, Eddy

AU - Noutsi, Pakiza

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background: The drug-metabolizing enzyme CYP2E1 is of great interest in environmental medicine because of its involvement in the bioactivation of multiple procarcinogens. Aim: This study is aimed at determining the frequency of genetic polymorphisms of the three restriction fragment length polymorphisms: PstI and RsaI (CYP2E1*5B) and DraI (CYP2E1*6) in 216 cancer-free Lebanese individuals, as well as assessing potential association with morbid diseases in this specific population. Results: The frequency of C-T allele of CYP2E*5B was 0.7% and that of A CYP2E1*6 was 6.3%. All those who carried the CYP2E1*5B allele also carried the CYP2E1*6 allele. There was a significant decrease in coronary artery disease incidence in patients carrying a CYP2E1*6 genetic polymorphism (39.7% of the noncarriers vs. 13.6% of the carriers had coronary artery disease; p=0.019); similar results were found with the haplotype analysis (p=0.03) but not with CYP2E1*5B alone. Conclusion: This is the first study on the genetic polymorphism of CYP2E1 in a Lebanese population. These data will be useful for future assessment of the role of CYP2E1 polymorphisms in the cancer population in Lebanon. It is recommended that careful population selection be performed in designing case-control studies that evaluate the association between CYP2E1 and cancer incidence. The most important factors to be controlled for are sex, body mass index, environmental exposure, lifestyle habits, and possibly, history of coronary artery disease.

AB - Background: The drug-metabolizing enzyme CYP2E1 is of great interest in environmental medicine because of its involvement in the bioactivation of multiple procarcinogens. Aim: This study is aimed at determining the frequency of genetic polymorphisms of the three restriction fragment length polymorphisms: PstI and RsaI (CYP2E1*5B) and DraI (CYP2E1*6) in 216 cancer-free Lebanese individuals, as well as assessing potential association with morbid diseases in this specific population. Results: The frequency of C-T allele of CYP2E*5B was 0.7% and that of A CYP2E1*6 was 6.3%. All those who carried the CYP2E1*5B allele also carried the CYP2E1*6 allele. There was a significant decrease in coronary artery disease incidence in patients carrying a CYP2E1*6 genetic polymorphism (39.7% of the noncarriers vs. 13.6% of the carriers had coronary artery disease; p=0.019); similar results were found with the haplotype analysis (p=0.03) but not with CYP2E1*5B alone. Conclusion: This is the first study on the genetic polymorphism of CYP2E1 in a Lebanese population. These data will be useful for future assessment of the role of CYP2E1 polymorphisms in the cancer population in Lebanon. It is recommended that careful population selection be performed in designing case-control studies that evaluate the association between CYP2E1 and cancer incidence. The most important factors to be controlled for are sex, body mass index, environmental exposure, lifestyle habits, and possibly, history of coronary artery disease.

UR - http://www.scopus.com/inward/record.url?scp=77954940821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954940821&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2009.0193

DO - 10.1089/gtmb.2009.0193

M3 - Article

C2 - 20406102

AN - SCOPUS:77954940821

VL - 14

SP - 393

EP - 397

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 3

ER -